TY - JOUR

T1 - Application of monoterpenoids and their derivatives for treatment of neurodegenerative disorders

AU - Volcho, Konstantin P.

AU - Laev, Sergey S.

AU - Ashraf, Ghulam Md

AU - Aliev, Gjumrakch

AU - Salakhutdinov, Nariman F.

N1 - Publisher Copyright: © 2018 Bentham Science Publishers.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.

AB - Neurodegenerative disorders (NDDs) like Alzheimer's disease, Parkinson’s disease and Huntington’s disease are a heterogeneous group of disorders with the progressive and severe loss of neurons. There are no full proof cures for these diseases, and only medicines are available that can alleviate some of the symptoms. Developing effective treatments for the NDDs is a difficult but necessary task. Hence, the investigation of monoterpenoids which modulate targets applicable to many NDDs is highly relevant. Many monoterpenoids have demonstrated promising neuroprotective activity mediated by various systems. It can form the basis for elaboration of agents which will be useful both for the alleviation of symptoms of NDDs and for the treatment of diseases progression and also for prevention of neurodegeneration. The further developments including detections of monoterpenoids and their derivatives with high neuroprotective or neurotrophic activity as well as the results of qualified clinical trials are needed to draw solid conclusions regarding the efficacy of these agents.

KW - Acetylcholinesterase inhibitors

KW - Alzheimer's disease

KW - Cannabinoids

KW - Huntington’s disease

KW - Monoterpenes

KW - Monoterpenoids

KW - Neuroprotective activity

KW - Parkinson’s disease

KW - Humans

KW - Neuroprotective Agents/chemistry

KW - Brain Ischemia/metabolism

KW - Animals

KW - Neurodegenerative Diseases/drug therapy

KW - Cholinesterase Inhibitors/chemistry

KW - Receptor, Cannabinoid, CB2/antagonists & inhibitors

KW - Monoterpenes/chemistry

KW - Acetylcholinesterase/chemistry

KW - Receptor, Cannabinoid, CB1/antagonists & inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85024861710&partnerID=8YFLogxK

U2 - 10.2174/0929867324666170112101837

DO - 10.2174/0929867324666170112101837

M3 - Review article

C2 - 28079000

AN - SCOPUS:85024861710

VL - 25

SP - 5327

EP - 5346

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 39

ER -